MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome



: Maria NI, Brkic Z, Waris M, van Helden-Meeuwsen CG, Heezen K, van de Merwe JP, van Daele PL, Dalm VASH, Drexhage HA, Versnel MA

Publisher: BMJ PUBLISHING GROUP

: 2014

: Annals of the Rheumatic Diseases

: ANNALS OF THE RHEUMATIC DISEASES

: ANN RHEUM DIS

: 73

: 6

: 1052

: 1059

: 8

: 0003-4967

DOI: https://doi.org/10.1136/annrheumdis-2012-202552


Conclusions The MxA assays were excellent tools to assess IFN type I activity in pSS, MxA-EIA being the most practical. MxA levels associate with features of active disease and are reduced in hydroxychloroquine-treated patients, suggesting the clinical applicability of MxA in stratifying patients according to IFN positivity.




Last updated on 2024-26-11 at 23:52